[ad_1]
The analysis revealed within the Journal of Infection investigated using metagenomic next-generation sequencing (mNGS) in diagnosing bloodstream infections (BSIs) for immunocompromised hematology sufferers. Hematology sufferers are extremely vulnerable to BSIs, which might have extreme penalties corresponding to septic shock, multiple-organ failure, disseminated intravascular coagulation, and even loss of life. An correct and fast microbiological analysis of BSI is due to this fact important for the management of the an infection.
Characteristics of 256 immunocompromised sufferers with suspected bloodstream infections view extra
Image Credit: BGI Genomics
In the examine, performed between January 2019 and December 2020 at Tongji Hospital with the participation of BGI Genomics researcher Wenqian Zhang, peripheral blood samples have been collected from 256 immunocompromised hematology sufferers suspected of BSI, and each mNGS and traditional microbiological assessments (CMTs) have been carried out. BSI analysis was confirmed in 189 out of 256 sufferers (73.8%). The detection charge of mNGS was considerably greater than that of CMTs, with mNGS figuring out 187 an infection circumstances and CMTs figuring out 81. Results point out mNGS outperformed CMT in detecting bloodstream infections.
Bacteria have been detected in 17 sufferers (6.6%), fungi in 15 sufferers (5.9%), uncommon pathogens in 4 sufferers (1.6%), and a number of species in 55 sufferers (21.5%).
Based on mNGS outcomes, viral an infection was probably the most frequent BSI, recognized in 96 out of 256 sufferers (37.5%). The 5 commonest causative viruses have been CMV (31.3%), EBV (14.8%), HSV1 (11.7%), BK virus (11.7%) and HHV6B (9.4%).
The outcomes additionally confirmed that it was extra probably for sufferers who had undergone hematopoietic stem cell transplantation (HSCT), than those that had not, to be contaminated by BK virus and HHV6B.
Overall, the examine highlights the potential of mNGS as a robust instrument for the speedy and correct analysis of BSIs in immunocompromised hematology sufferers, permitting for well timed and efficient remedy.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen China, is the world’s main built-in options supplier of precision medication. Our providers cowl over 100 nations and areas, involving greater than 2,300 medical establishments. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was formally listed on the Shenzhen Stock Exchange.